Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 May 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2022 Apr 18;89(5):721–735. doi: 10.1007/s00280-022-04430-6

Table 4.

Best responses in BRCAmut and BRCAwt cohorts.

	BRCAmut							BRCAwt

	#Evaluable	CR	PR	SD	PD	ORR (%)	CBR (%)^*	#Evaluable	PR	SD	PD	ORR (%)	CBR^* (%)

All Patients	62	1	13	20	28	14/62 (23%)	26/62 (42%)	25	2	7	16	2/25 (8%)	4/25 (16%)

By Primary Tumor
Ovarian	33	0	6	10	17	6/33 (18%)	14/33 (42%)	3	0	1	2	0/3 (0%)	0/3 (0%)
Breast	15	0	4	4	7	4/15 (27%)	5/15 (33%)	22	2	6	14	2/22 (9%)	4/22 (18%)
Fallopian Tube	4	0	1	2	1	1/4 (25%)	2/4 (50%)
Peritoneal	3	1	0	2	0	1/3 (33%)	1/3 (33%)
Prostate	3	0	2	1	0	2/3 (67%)	3/3 (100%)
Pancreatic	1	0	0	0	1	0/1 (0%)	0/1 (0%)
Endometrium	1	0	0	1	0	0/1 (0%)	1/1 (100%)
Kidney	1	0	0	0	1	0/1 (0%)	0/1 (0%)
Unknown	1	0	0	0	1	0/1 (0%)	0/1 (0%)

By Dose Level
DL1	7	0	0	0	7	0/7 (0%)	0/7 (0%)	3	1	0	2	1/3 (33%)	1/3 (33%)
DL2	3	0	0	2	1	0/3 (0%)	2/3 (67%)	3	0	1	2	0/3 (0%)	0/3 (0%)
DL3	3	0	0	1	2	0/3 (0%)	1/3 (33%)	3	1	0	2	1/3 (33%)	1/3 (33%)
DL4	3	0	0	2	1	0/3 (0%)	1/3 (33%)	3	0	0	3	0/3 (0%)	0/3 (0%)
DL5	3	0	0	1	2	0/3 (0%)	0/3 (0%)	3	0	1	2	0/3 (0%)	0/3 (0%)
DL6	4	0	0	3	1	0/4 (0%)	2/4 (50%)	3	0	2	1	0/3 (0%)	1/3 (33%)
DL7	4	0	1	1	2	1/4 (25%)	2/4 (50%)	2	0	1	1	0/2 (0%)	1/2 (50%)
DL8	30	0	12	8	10	12/30 (40%)	16/30 (53%)	5	0	2	3	0/5 (0%)	0/5 (0%)
DL9	5	1	0	2	2	1/5 (20%)	2/5 (40%)

^*

CBR defined as CR, PR, or SD ≥ 6 cycles